Loading...
New

Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End User (Pediatrics and Adults): Global Opportunity Analysis and Industry Forecast, 2020–2027

A01134
Pages: 284
Jul 2020 | 10188 Views
 
Author(s) : Sanjivan Gill, Sushant Terdale , Onkar Sumant
Tables: 144
Charts: 34
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cancer Vaccines Market

Request Now !

The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027.

Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. Preventive cancer vaccines are used in healthy person to prevent cancer. Therapeutic cancer vaccines are used in cancer patients to strengthen their immune response to fight against the disease. Cancer vaccines can be administered intravenously (IV) in children as well as in adults.


 Cancer Vaccines Market

Get more information on this report : Request Sample Pages

 

Increase in number of cancer patients, rise in geriatric population, surge in patient awareness towards cancer therapy, increase in cancer vaccines usage combined with other therapies, increase in prevalence of human papilloma virus (HPV) infections, and increase in investments and government funding in development of cancer vaccines by manufacturers are the major factors that drive growth of the cancer vaccines market. In addition, technological developments in cancer vaccines, launch of novel cancer vaccines, rise in health care services and expenditure, and rise in adoption rates of preventive and therapeutic vaccines are some other factors that contribute toward growth of the market. Moreover, increase in tobacco consumption and unhealthy dietary habits are leading risk factors for the rise in number of cancer cases, which further drives growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth.

Cancer Vaccines Market
By Technology

Your browser does not support the canvas element.

Recombinant Cancer Vaccines segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

COVID-19 Impact on Cancer Vaccines Market

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Cancer vaccines manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shutdown in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.

Cancer Vaccines Market
By Type

Your browser does not support the canvas element.

Preventive Cancer Vaccines segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Cancer Vaccines Market Segmentation  

The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Cancer Vaccines Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 15.0% during 2019-2026.

Get more information on this report : Request Sample Pages

Segment Review 

Presently, on the basis of technology, the recombinant cancer vaccines segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in number of approved cancer vaccines developed using recombinant technology are the key factors that boost growth of the segment.

Depending on indication, the cervical cancer segment is the major shareholder in the global cancer vaccines market, owing to high prevalence of cervical cancer and increase in number of people suffering from human papilloma virus (HPV) infections. In addition, rise in geriatric population, drug development in the field of cervical cancer, and increase in patient awareness toward cervical cancer drive growth of the segment.  

Snapshot of Asia-Pacific Cancer Vaccines Market  

Asia-Pacific presents lucrative opportunities for key players operating in the cancer vaccines market, owing to rise in adoption of cancer vaccines, increase in number of cancer patients in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in cancer vaccines. Moreover, rise in demand for cancer vaccines, surge in funding from government and non-government sectors to develop novel cancer vaccines, rise in number of hospitals & diagnostic centers equipped with advanced medical facilities, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the cancer vaccines market in the region.

The key players profiled in this report include Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc (GSK), Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Group Co. Ltd. (Dendereon Corporation), UbiVac, and Vaccinogen, Inc.

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the cancer vaccines market size along with the current trends and future estimations to elucidate imminent investment pockets.
  • It offers cancer vaccines market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global cancer vaccines market growth.

Key Market Segments:

By Technology 

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines

By Indication

  • Cervical Cancer
  • Prostate Cancer
  • Others 

By Type

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines 

By End User

  • Pediatrics 
  • Adults 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Turkey
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments

1.3.1. List of key players profiled in the report

1.4. Research Methodology

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition and Scope
3.2. Key Findings

3.2.1. Top investment pockets.
3.2.2. Top winning strategies

3.3. Porter’s five force analysis
3.4. Regulatory Framework

3.4.1. FDA
3.4.2. CE Mark
3.4.3. Therapeutic Goods Administration (TGA)
3.4.4. Ministry of Health, Labour and Welfare (MHLW)

3.5. Market Share Analysis, 2019
3.6. Market Dynamics

3.6.1. Drivers

3.6.1.1. Rise in prevalence of human papilloma virus (HPV) cancer
3.6.1.2. Increase in administration of prophylactic cancer vaccines
3.6.1.3. Rise in development of new cancer vaccines
3.6.1.4. Launch and approval of new cancer vaccines in the market

3.6.2. Restraints

3.6.2.1. High cost and longer timelines required for development of cancer vaccines

3.6.3. Opportunities

3.6.3.1. High growth prospects in emerging markets

3.6.4. Impact analysis

CHAPTER 4: CANCER VACCINES MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Dendritic Cells (DC) Cancer Vaccines

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country

4.3. Recombinant Cancer Vaccines

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

4.4. Antigen/Adjuvent Cancer Vaccines

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country

4.5. Viral Vector and DNA Cancer Vaccines

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

CHAPTER 5: CANCER VACCINES MARKET, BY TYPES

5.1. Overview
5.2. Market size and forecast
5.3. Preventive Cancer Vaccines

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Therapeutic Cancer Vaccines

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: CANCER VACCINES MARKET, BY INDICATION

6.1. Overview
6.2. Market size and forecast
6.3. Cervical Cancer

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Prostate Cancer

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

6.5. Other Indications

6.5.1. Market size and forecast, by region
6.5.2. Market analysis, by country

CHAPTER 7: CANCER VACCINES MARKET, BY END USER

7.1. Overview
7.2. Market size and forecast
7.3. Pediatrics

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

7.4. Adults

7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country

CHAPTER 8: CANCER VACCINES MARKET, BY REGION

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends, growth factors, and opportunities
8.2.2. North America cancer vaccines market, by country

8.2.2.1. U.S.

8.2.2.1.1. U.S. cancer vaccines market, by technology
8.2.2.1.2. U.S. cancer vaccines market, by type
8.2.2.1.3. U.S. cancer vaccines market, by Indication
8.2.2.1.4. U.S. cancer vaccines market, by end user

8.2.2.3. Canada

8.2.2.3.1. Canada cancer vaccines market, by technology
8.2.2.3.2. Canada cancer vaccines market, by type
8.2.2.3.3. Canada cancer vaccines market, by indication
8.2.2.3.4. Canada cancer vaccines market, by end user

8.2.2.5. Mexico

8.2.2.5.1. Mexico cancer vaccines market, by technology
8.2.2.5.2. Mexico cancer vaccines market, by type
8.2.2.5.3. Mexico cancer vaccines market, by indication
8.2.2.5.4. Mexico cancer vaccines market, by end user

8.2.3. North America cancer vaccines market, by technology
8.2.4. North America cancer vaccines market, by type
8.2.5. North America cancer vaccines market, by indication
8.2.6. North America cancer vaccines market, by end user

8.3. Europe

8.3.1. Key market trends, growth factors, and opportunities
8.3.2. Europe cancer vaccines market, by country

8.3.2.1. Germany

8.3.2.1.1. Germany cancer vaccines market, by technology
8.3.2.1.2. Germany cancer vaccines market, by type
8.3.2.1.3. Germany cancer vaccines market, by indication
8.3.2.1.4. Germany cancer vaccines market, by end user

8.3.2.2. France

8.3.2.2.1. France cancer vaccines market, by technology
8.3.2.2.2. France cancer vaccines market, by type
8.3.2.2.3. France cancer vaccines market, by indication
8.3.2.2.4. France cancer vaccines market, by end user

8.3.2.3. UK

8.3.2.3.1. UK cancer vaccines market, by technology
8.3.2.3.2. UK cancer vaccines market, by type
8.3.2.3.3. UK cancer vaccines market, by indication
8.3.2.3.4. UK cancer vaccines market, by end user

8.3.2.4. Italy

8.3.2.4.1. Italy cancer vaccines market, by technology
8.3.2.4.2. Italy cancer vaccines market, by type
8.3.2.4.3. Italy cancer vaccines market, by indication
8.3.2.4.4. Italy cancer vaccines market, by end user

8.3.2.5. Spain

The Spain cancer vaccines market was valued at $107.67 million in 2019, and is projected to reach $158.00 million by 2027, registering a CAGR of 9.5%.

8.3.2.5.1. Spain cancer vaccines market, by technology
8.3.2.5.2. Spain cancer vaccines market, by type
8.3.2.5.3. Spain cancer vaccines market, by indication
8.3.2.5.4. Spain cancer vaccines market, by end user

8.3.2.6. Rest of Europe

8.3.2.6.1. Rest of Europe cancer vaccines market, by technology
8.3.2.6.2. Rest of Europe cancer vaccines market, by type
8.3.2.6.3. Rest of Europe cancer vaccines market, by indication
8.3.2.6.4. Rest of Europe cancer vaccines market, by end user

8.3.3. Europe cancer vaccines market, by technology
8.3.4. Europe cancer vaccines market, by type
8.3.5. Europe cancer vaccines market, by indication
8.3.6. Europe cancer vaccines market, by end user

8.4. Asia-Pacific

8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific cancer vaccines market, by country

8.4.2.1. Japan

8.4.2.1.1. Japan cancer vaccines market, by technology
8.4.2.1.2. Japan cancer vaccines market, by type
8.4.2.1.3. Japan cancer vaccines market, by indication
8.4.2.1.4. Japan cancer vaccines market, by end user

8.4.2.2. China

8.4.2.2.1. China cancer vaccines market, by technology
8.4.2.2.2. China cancer vaccines market, by type
8.4.2.2.3. China cancer vaccines market, by indication
8.4.2.2.4. China cancer vaccines market, by end user

8.4.2.3. Australia

8.4.2.3.1. Australia cancer vaccines market, by technology
8.4.2.3.2. Australia cancer vaccines market, by type
8.4.2.3.3. Australia cancer vaccines market, by indication
8.4.2.3.4. Australia cancer vaccines market, by end user

8.4.2.4. India

8.4.2.4.1. India cancer vaccines market, by technology
8.4.2.4.2. India cancer vaccines market, by type
8.4.2.4.3. India cancer vaccines market, by indication
8.4.2.4.4. India cancer vaccines market, by end user

8.4.2.5. South Korea

8.4.2.5.1. South Korea cancer vaccines market, by technology
8.4.2.5.2. South Korea cancer vaccines market, by type
8.4.2.5.3. South Korea cancer vaccines market, by indication
8.4.2.5.4. South Korea cancer vaccines market, by end user

8.4.2.6. Rest of Asia-Pacific

8.4.2.6.1. Rest of Asia-Pacific cancer vaccines market, by technology
8.4.2.6.2. Rest of Asia-Pacific cancer vaccines market, by type
8.4.2.6.3. Rest of Asia-Pacific cancer vaccines market, by indication
8.4.2.6.4. Rest of Asia-Pacific cancer vaccines market, by end user

8.4.3. Asia-Pacific cancer vaccines market, by technology
8.4.4. Asia-Pacific cancer vaccines market, by type
8.4.5. Asia-Pacific cancer vaccines market, by indication
8.4.6. Asia-Pacific cancer vaccines market, by end user

8.5. LAMEA

8.5.1. Key market trends, growth factors, and opportunities
8.5.2. LAMEA cancer vaccines market, by country

8.5.2.1. Brazil

8.5.2.1.1. Brazil cancer vaccines market, by technology
8.5.2.1.2. Brazil cancer vaccines market, by type
8.5.2.1.3. Brazil cancer vaccines market, by indication
8.5.2.1.4. Brazil cancer vaccines market, by end user

8.5.2.2. Argentina

8.5.2.2.1. Argentina  cancer vaccines market, by technology
8.5.2.2.2. Argentina  cancer vaccines market, by type
8.5.2.2.3. Argentina cancer vaccines market, by indication
8.5.2.2.4. Argentina cancer vaccines market, by end user

8.5.2.3. Turkey

8.5.2.3.1. Turkey cancer vaccines market, by technology
8.5.2.3.2. Turkey cancer vaccines market, by type
8.5.2.3.3. Turkey  cancer vaccines market, by indication
8.5.2.3.4. Turkey  cancer vaccines market, by end user

8.5.2.4. South Africa

8.5.2.4.1. South Africa cancer vaccines market, by technology
8.5.2.4.2. South Africa cancer vaccines market, by type
8.5.2.4.3. South Africa cancer vaccines market, by indication
8.5.2.4.4. South Africa cancer vaccines market, by end user

8.5.2.5. Rest of LAMEA

8.5.2.5.1. Rest of LAMEA cancer vaccines market, by technology
8.5.2.5.2. Rest of LAMEA cancer vaccines market, by type
8.5.2.5.3. Rest of LAMEA cancer vaccines market, by indication
8.5.2.5.4. Rest of LAMEA cancer vaccines market, by end user

8.5.3. LAMEA cancer vaccines market, by technology
8.5.4. LAMEA cancer vaccines market, by type
8.5.5. LAMEA cancer vaccines market, by indication
8.5.6. LAMEA cancer vaccines market, by end user

CHAPTER 9: COMPANY PROFILES

9.1. Advaxis Inc.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments

9.2. Amgen Inc.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance

9.3. Dynavax Technologies Corporation

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. Generex Biotechnology Corporation

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. GlaxoSmithKline plc (GSK)

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. Immunocellular Therapeutics, Ltd

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio

9.7. Merck & Co., Inc.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Key strategic moves and developments

9.9. UbiVac

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Key strategic moves and developments

9.10. Vaccinogen, Inc.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio

LIST OF TABLES

TABLE 01. GLOBAL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 02. DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 03. RECOMBINANT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 04. ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 05. VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 06. GLOBAL CANCER VACCINES MARKET, BY TYPES, 2019-2027 ($MILLION)
TABLE 07. PREVENTIVE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 08. THERAPEUTIC CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 09. GLOBAL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 10. CERVICAL CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 11. PROSTATE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 12. OTHERS INDICATIONS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 13. GLOBAL CANCER VACCINES MARKET REVENUE, BY END USER, 2019-2027 ($MILLION)
TABLE 14. PEDIATRICS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 15. ADULTS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 16. CANCER VACCINES MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
TABLE 17. NORTH AMERICA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 18. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 19. U.S. CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 20. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 21. U.S. CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 22. CANADA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 23. CANADA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 24. CANADA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 25. CANADA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 26. MEXICO CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 27. MEXICO CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28. MEXICO CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 29. MEXICO CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 30. NORTH AMERICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 31. NORTH AMERICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 32. NORTH AMERICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 33. NORTH AMERICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 34. EUROPE CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 35. GERMANY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 36. GERMANY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 37. GERMANY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 38. GERMANY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 39. FRANCE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 40. FRANCE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 41. FRANCE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 42. FRANCE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 43. UK CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 44. UK CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 45. UK CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 46. UK CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 47. ITALY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 48. ITALY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 49. ITALY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 50. ITALY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 51. SPAIN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 52. SPAIN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 53. SPAIN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 54. SPAIN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 55. REST OF EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 56. REST OF EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 57. REST OF EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 58. REST OF EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 59. EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 60. EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 61. EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 62. EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 63. ASIA-PACIFIC CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 64. JAPAN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 65. JAPAN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 66. JAPAN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 67. JAPAN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 68. CHINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 69. CHINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 70. CHINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 71. CHINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 72. AUSTRALIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 73. AUSTRALIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 74. AUSTRALIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 75. AUSTRALIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 76. INDIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 77. INDIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 78. INDIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 79. INDIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 80. SOUTH KOREA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 81. SOUTH KOREA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 82. SOUTH KOREA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 83. SOUTH KOREA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 88. ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 89. ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 90. ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 91. ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 92. LAMEA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 93. BRAZIL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 94. BRAZIL CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 95. BRAZIL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 96. BRAZIL CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 97. ARGENTINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 98. ARGENTINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 99. ARGENTINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 100. ARGENTINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 101. TURKEY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 102. TURKEY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 103. TURKEY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 104. TURKEY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 105. SOUTH AFRICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 106. SOUTH AFRICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 107. SOUTH AFRICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 108. SOUTH AFRICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 109. REST OF LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 110. REST OF LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 111. REST OF LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 112. REST OF LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 113. LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 114. LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 115. LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 116. LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 117. ADVAXIS: COMPANY SNAPSHOT
TABLE 118. ADVAXIS: PRODUCT PORTFOLIO
TABLE 119. ADVAXIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. AMGEN: COMPANY SNAPSHOT
TABLE 121. AMGEN: PRODUCT PORTFOLIO
TABLE 122. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 123. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 124. GENEREX BIOTECHNOLOGY: COMPANY SNAPSHOT
TABLE 125. GENEREX BIOTECHNOLOGY: PRODUCT PORTFOLIO
TABLE 126. GSK: COMPANY SNAPSHOT
TABLE 127. GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 128. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 129. GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. IMMUNOCELLULAR: COMPANY SNAPSHOT
TABLE 131. IMMUNOCELLULAR: PRODUCT PORTFOLIO
TABLE 132. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 133. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 134. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 135. MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 136. SANPOWER GROUP: COMPANY SNAPSHOT
TABLE 137. SANPOWER GROUP: OERATING SEGMENT
TABLE 138. SANPOWER GROUP: PRODUCT PORTFOLIO
TABLE 139. SANPOWER GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 140. UBIVAC: COMPANY SNAPSHOT
TABLE 141. UBIVAC.: PRODUCT PORTFOLIO
TABLE 142. UBIVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143. VACCINOGEN: COMPANY SNAPSHOT
TABLE 144. VACCINOGEN: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL CANCER VACCINES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2019
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2019
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2019
FIGURE 06. MODERATE POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. HIGH THREAT OF SUBSTITUTION
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH COMPETITIVE RIVALRY
FIGURE 11. MARKET SHARE ANALYSIS, 2019
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREVENTIVE CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS THERAPEUTIC CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PADIATRICS CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ADULTS CANCER VACCINES MARKET,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 24. ADVAXIS NET SALES, 2017–2019 ($MILLION)
FIGURE 25. AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 26. AMGEN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 27. DYNAVAX TECHNOLOGIES: NET SALES, 2017–2019 ($MILLION)
FIGURE 28. GENEREX BIOTECHNOLOGY: NET SALES, 2018–2019 ($MILLION)
FIGURE 29. GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 30. GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31. GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32. MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 33. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 34. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2019 (%)

 
 

Cancer vaccines are medications that stimulate the immune system of the body to fight against disease. Moreover, it can be administered intravenously in children as well as adults. 

Rise in prevalence of cancer, increase in demand for novel cancer vaccine products, rise in adoption rates of preventive and therapeutic vaccines, and rise in investments by government & private organizations for the production of cancer vaccines significantly boost growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time required for manufacturing a single vaccine are anticipated to restrict the market growth.

North America is expected to remain dominant during the forecast period, owing to rise in cases of cancer, high unmet demand for cancer vaccines, higher healthcare awareness, presence of well-developed healthcare infrastructure, presence of trained medical professionals, and early detection of the disease, which supports the market growth. In addition, strong reimbursement policies, presence of large number of hospitals & diagnostic centers equipped with advanced healthcare systems, and strong presence of key players supplement growth of the market in the region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to rise in number of cancer affected population with rise in demand for cancer vaccines.

 

 

 

 

 

 

 

 

 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Cancer Vaccines market is $4,187.62 million in 2019.

A. The forcast period for Cancer Vaccines market is 2020 to 2027

A. The market value of Cancer Vaccines market in 2020 is $3,345.07 million.

A. The base year is 2019 in Cancer Vaccines market

A. Top companies such as Merck & Co., Inc., Amgen Inc., GlaxoSmithKline plc, Dynavax Technologies, and Sanpower Group Co., Ltd. (Dendron) held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Recombinant cancer vaccines segment is the most influencing segment owing to recombinant cancer vaccines are most efficient alternative to traditional vaccines in the prevention of various human diseases, and rise in adaption due to rapid elimination of risk of active infection.

A. The major factor that fuels the growth of the global Cancer Vaccines market includes rise in prevalence of cancer such as breast cancer, prostate cancer, cervical, lung cancer, and others globally, and surge in investments and governmental funding in the development of cancer vaccines by manufacturers, increase in cancer usage combined with other therapies, surge in demand for cancer vaccines, rise in public awareness towards benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines.

A. The major factor that fuels the growth of the global Cancer Vaccines market includes rise in prevalence of cancer such as breast cancer, prostate cancer, cervical, lung cancer, and others globally, and surge in investments and governmental funding in the development of cancer vaccines by manufacturers, increase in cancer usage combined with other therapies, surge in demand for cancer vaccines, rise in public awareness towards benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 17.0%. This is due to rise in adoption of cancer vaccines treatment medication, increase in number of cancer patients, rise in demand for cancer vaccines, improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & diagnostic centers equipped with advanced medical facilities

A. Cancer vaccine is a type of immunotherapy that boosts the natural defense of the body by stimulating the immune system to recognize and cure cancerous cells.

A. Cancer vaccine is a type of immunotherapy that boosts the natural defense of the body by stimulating the immune system to recognize and cure cancerous cells.

A. Cancer Vaccines products are used to effectively fight against cancer disease.

A. Cancer Vaccines products are used to effectively fight against cancer disease.

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cancer Vaccines Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts